The German biotech company is behind a leading candidate for the bioentech coronavirus vaccine, which has been approved by the U.S. Located pharmaceutical company has jointly developed with Pfizer. And according to its CEO, the 90% effective vaccine candidate is ready to end the global epidemic. Search the UK newspaper The Guardian On Zoom, Byantech CEO Ugur Sahin said he was optimistic about the success of the vaccine. “If the question arises as to whether we can prevent this epidemic with this vaccine, my answer is: yes, because I believe that only therapeutic infections will also be protected. A dramatic effect,” he told the UK daily. Sahin explained that he was not fully confident at first, but that had all changed since the Phase III trial results were announced last Monday. The way it works is by attacking the virus in a variety of ways, first by making it harder for the virus to enter the body, and then by training its immune system to fight back. This vaccine prevents COVID-19 from gaining access to our cells. But even if the virus manages to find a way, the T-cells will hit it head on and remove it, “he said. The Guardian. “We have trained the immune system very well to complete these two defensive moves. We now know that viruses cannot defend themselves against these mechanisms. There are still some questions about vaccines, such as how long vaccine immunity can last. Sahin explained The GuardianHowever, “Studies of COVID-19 patients have shown that people with a strong immune response respond even after six months. I can imagine we would be safe for at least a year.”

The Pfizer-Bioentech candidate is seen by many as the most likely to win the vaccine race, with nations around the world trying to secure the means to end the growing epidemic by the end of 2019. Following the results of their Phase III test, which was last announced on Monday, the Israeli government signed a formal agreement on Friday, with the Israeli government also taking notice. Receive eight million doses in January It must succeed. “This is a great day for the state of Israel and the way to our victory against the coronavirus,” Prime Minister Benjamin Netanyahu said Friday. “Today we saw a light at the end of the tunnel.” But other vaccine candidates also look promising. One of them, the US-based firm Modern, is also confident that it will have a candidate. Just as good or better than its competitors“Our vaccine produces antibodies in the body … which means that in addition to being a rookie vaccine, our product can also be used to treat infected people. We have shown that the product mimics the virus,” its chief medical officer Tal Zex explained in late October. Prevents and improves the patient’s condition. “Similarly, Israel has also signed an agreement with Moderna, and the Hadassah-University Medical Center in Jerusalem has signed a memorandum of understanding with Russia to receive its Sputnik V vaccine candidate, the report said. Has an effectiveness rate of 92%.Mayan Hoffman and Tobias Siegel contributed to this report.